New cancer drug trial seeks to target advanced tumors
NCT ID NCT05163041
Summary
This early-stage study is testing a new drug called BT7480, both by itself and combined with an existing immunotherapy (nivolumab), in people with advanced solid tumors. The main goals are to find the safest and most effective dose and to learn about the drug's side effects and how well it might shrink tumors. The trial is for patients whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
START Center for Cancer Care
San Antonio, Texas, 78229, United States
-
State University of Iowa
Iowa City, Iowa, 52242, United States
-
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.